Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

442.33 +5.84 (+1.34%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
42 43 Next >
China PMI Surprises To Upside
Good Morning Everyone! China stuns the world with manufacturing activity expanding at the fastest pace in more than a decade in February.  The Hong Kong stock index is up +4%. Maybe the economy won’t... 
Via Benzinga
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price... 
Via Benzinga
Diabetes Behemoth Eli Lilly Slashes Insulin Prices By 70%
The company also plans to cap out-of-pocket costs at $35 per month in one program. 
Via Investor's Business Daily
Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race
 
Via Benzinga
$100 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much $100 Invested In Eli Lilly 10 Years Ago Would Be Worth Today
 
Via Benzinga
7 Mega-Cap Stocks to Buy for the Long Haul
If you’re looking for a stock you can buy and hold for a long time, then these mega-cap stocks to by fit the bill. 
Via InvestorPlace
3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End
These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch. 
Via InvestorPlace
7 Dynamite Dividend Stocks for Income and Growth in 2023
These dividend stocks boast both impressive growth profiles and reliable dividend income for 2023 and the long-term. 
Via InvestorPlace
Why Nektar Therapeutics Stock Is Plunging Today
 
Via Benzinga
US Stocks Stare At More Losses In a Lackluster Week: Can Inflation Data Salvage Year's Rally?
See-sawing sentiment continues to persist on Wall Street, as index futures signal weakness on Friday after Thursday's positive close. A key inflation reading due ahead of the market opening may largely... 
Via Benzinga
Eli Lilly's Says Inventory For Diabetes Mounjaro Is Available, Probably Ending Shortage
Eli Lilly And Co (NYSE: LLY) said that all doses of its new diabetes drug Mounjaro (tirzepatide) were now available, with wholesalers having inventory after a two-month-long shortage. 
Via Benzinga
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
This Recession-Proof Company Has a Best-in-Class Dividend
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
3 Top Defensive Stocks to Buy Hand Over Fist Right Now
These three defensive stocks could cushion your portfolio from market volatility this year. 
Via The Motley Fool
Is This Supercharged Growth Stock a Buy?
Shares of this drugmaker have trounced the S&P 500 index in the last decade. 
Via The Motley Fool
Should Income Investors Buy This Dow Jones Stock?
This drugmaker boasts an impressive product portfolio and pipeline. 
Via The Motley Fool
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029). 
Via SBWire
US Stocks' Resilience Faces Test As Traders Await Flurry Of Economic Data: Fed May 'Surprise To The Upside' On Rates Again In 2023, Says Analyst
The resilient market faces another test on Thursday, as traders get to digest another set of economic data and a few Fed speeches. The index futures pointed to a cautious start on Thursday. Cues From... 
Via Benzinga
7 Hot Healthcare Stocks With the Potential to Outperform
These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong. 
Via InvestorPlace
Which Healthcare Stock Is a Better Pick in 2023?
With a potential recession on the horizon, healthcare stocks could be good picks for investors. Which of these three is best? 
Via InvestorPlace
7 Great Growth Stocks to Buy in February
Poised to be long-term winners, consider now the perfect time to enter/add to positions in these 7 high-quality growth stocks to buy. 
Via InvestorPlace
Tuesday Talk: My Sweet CPI
The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday. 
Via Talk Markets
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
New 52-Week Highs In 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023. 
Via Talk Markets
Biggest US Pension Bulks Up On Tesla, Apple, And These Big Techs: How CalPERS Shuffled Its Portfolio In Q4
California Public Employees’ Retirement System, aka CalPERS, the biggest pension fund in the U.S., recently filed its 13F for the fourth quarter ended Dec. 30, with the SEC. 
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
Income stocks can lend portfolio growth in both up and down markets. 
Via The Motley Fool
7 A-Rated Healthcare Stocks to Buy for the Future of Medicine
Snapping up or adding to your positions in these healthcare stocks could be just what the doctor ordered for your portfolio. 
Via InvestorPlace
3 Surefire Growth Stocks You Can Buy Right Now
Maybe there's no such thing as a sure thing. But these stocks could come close. 
Via The Motley Fool
Gemcitabine HCL Market to Grow with a Growth Rate of 7% During 2023 to 2030
Gemcitabine HCL Market size is expected to reach at a CAGR of 7% during the forecast period (2023-2030). 
Via SBWire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.